Heparin Sodium Panpharma

Heparin Sodium Panpharma is a prescription‑only anticoagulant containing heparin sodium. It is supplied as an injectable solution for intravenous use, with the exact strength not disclosed. Marketed in the European Union, the drug belongs to the antithrombotic class and works by potentiating antithrombin III to inhibit clotting factors. It is administered under medical supervision to prevent thrombotic events, including deep vein thrombosis and pulmonary embolism in at‑risk patients.

Heparin Sodium Panpharma is indicated for several antithrombotic indications where rapid anticoagulation is required.

- Prevention and treatment of deep vein thrombosis (DVT) and its complications. - Prevention and treatment of pulmonary embolism (PE). - Anticoagulation during cardiac surgery, cardiopulmonary bypass, and other invasive procedures. - Management of acute coronary syndromes, including unstable angina and non‑ST‑segment elevation myocardial infarction. - Prophylaxis of clot formation in patients with high risk of thrombosis, such as those immobilized after major surgery.

Adverse reactions to Heparin Sodium Panpharma vary in frequency and severity.

Common: - Minor bleeding at the injection site or mild epistaxis. - Localized bruising or hematoma formation. - Transient elevation of liver enzymes. - Mild thrombocytopenia without clinical sequelae.

Serious: - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis. - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Spontaneous spinal or epidural hematoma leading to neurologic compromise.

Before initiating therapy with Heparin Sodium Panpharma, clinicians should evaluate several safety considerations.

- Assess baseline coagulation parameters and platelet count. - Review patient history for recent surgery, trauma, or active bleeding. - Use caution in patients with renal or hepatic impairment. - Avoid use in individuals with known hypersensitivity to heparin or pork‑derived products. - Monitor for signs of heparin‑induced thrombocytopenia during treatment. - Adjust dose in obese or underweight patients based on weight‑based protocols. - Consider pregnancy status, as safety data are limited.

Heparin Sodium Panpharma may interact with other agents that affect hemostasis or drug metabolism.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) or antiplatelet drugs (e.g., aspirin, clopidogrel) without dose adjustment. - High‑dose fibrinolytic therapy (e.g., alteplase) due to additive bleeding risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that impair platelet function.

Use with caution: - Thrombolytic agents administered in separate therapeutic windows. - Drugs that reduce platelet count (e.g., chemotherapy agents) increasing HIT risk. - Medications that bind plasma proteins and may alter heparin activity (e.g., protamine reversal agents).